SCM
ANRO icon

SCS Capital Management’s Alto Neuroscience ANRO Stock Holding History

SCS Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444K Hold
16,840
– – ﹤0.01% 372
2026
Q1 		$379K Sell
16,840
-16,549
-50% -$307K ﹤0.01% 381
2025
Q4 		$594K Sell
33,389
-33,388
-50% -$420K 0.01% 345
2025
Q3 		$268K Hold
66,777
– – ﹤0.01% 462
2025
Q2 		$147K Hold
66,777
– – ﹤0.01% 536
2025
Q1 		$144K Buy
+66,777
New +$239K ﹤0.01% 498

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

SCS Capital Management's ANRO Position: Q2 2026 in Review

SCS Capital Management held its Alto Neuroscience (ANRO) position steady in Q2 2026 at 16,840 shares worth $444K. The position accounts for ﹤0.01% of the portfolio, ranked #372.

SCS Capital Management first reported a position in ANRO in Q1 2025 and has held it in 6 quarters since. The position peaked at $594K in Q4 2025. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • SCS Capital Management held 16,840 shares of Alto Neuroscience worth $444K as of Q2 2026.
  • SCS Capital Management left its Alto Neuroscience share count unchanged in Q2 2026.
  • Alto Neuroscience made up ﹤0.01% of SCS Capital Management's portfolio in Q2 2026, its #372 holding.
  • SCS Capital Management first reported a position in Alto Neuroscience in Q1 2025 and has held it in 6 quarters since.
  • SCS Capital Management's Alto Neuroscience position peaked at $594K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.